When was Brenus Pharma founded?

Brenus Pharma was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Brenus Pharma located?

Brenus Pharma is headquartered in Issoire, France.

Who is the current CEO of Brenus Pharma?

Jacques Gardette of Brenus Pharma.

How many employees does Brenus Pharma have?

As of Jun 30, 2026, the latest employee count at Brenus Pharma is 28.

Is Brenus Pharma a funded company?

Brenus Pharma is a funded company, having raised a total of $43.4M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 18, 2024.

When was the latest funding round of Brenus Pharma?

Brenus Pharma's latest funding was a $***** Series A round on Jul 21, 2026, with participation from 6 investors. Its primary sector is Oncology. In France, the Oncology sector has seen $113M in funding in 2026 to date.

Where does Brenus Pharma rank among its competitors?

Brenus Pharma ranks 318th amongst 3297 active competitors, of which 1120 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Brenus Pharma, which secured $12.6M in Jul, 2026.

Who are the top competitors of Brenus Pharma?

Brenus Pharma's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Brenus Pharma secured the most recent funding round in July, 2026.

Brenus Pharma - 2026 Company Profile, Team, Funding & Competitors

Brenus Pharma is a series A company based in Issoire (France), founded in 2020. It operates as a Developer of immunotherapy for the treatment of cancer. Brenus Pharma has raised $43.4M in funding. The company has 3297 active competitors, including 1120 funded and 777 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immunotherapy for the treatment of cancer. The company's flagship product includes STC-1010 which is used to treat metastatic colorectal cancer (mCRC) and solid cancers.

Website: brenus-pharma.com
Social

Key Metrics

Founded Year

2020

Location

Issoire, France

Stage

Series A

Total Funding

$43.4M in 2 rounds

Latest Funding Round

Series A, Jul 21, 2026, $*****

Investors

UI Investissement & 9 more

Ranked

318^th among 3297 active competitors

Employee Count

28 as on Jun 30, 2026

Similar Companies

BeiGene & 586 more

View Brenus Pharma's full profile

Brenus Pharma has raised a total funding of $43.4M over 2 rounds. Its first funding round was on Sep 18, 2024. Its latest funding round was a Series A round on Jul 21, 2026 for $*****. 6 investors participated in its latest round. Brenus Pharma has 10 institutional investors.

Here is the list of recent funding rounds of Brenus Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 21, 2026	9120274	Series A	4390456	7419070	4006670	7036102
Sep 18, 2024	7740331	Series A	7239569	9322763	9362259	UI Investissement & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Brenus Pharma's funding rounds and investors

Brenus Pharma's employee count trend

Brenus Pharma has 28 employees as of Jun 26. Here is Brenus Pharma's employee count trend over the years:

Uncover Brenus Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Brenus Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Brenus Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
318th	Brenus Pharma 2020, Issoire (France), Series A	Developer of immunotherapy for the treatment of cancer	$43.4M	UI Investissement, Credit Agricole & 8 others	56/100